Head-to-head · free
The Precision Peptide Company vs Rivian
PNGAF vs RIVN — return on capital, cash generation, margins and balance sheet side by side.
PNGAF
0 / 0
measures where PNGAF leads
RIVN
0 / 0
measures where RIVN leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | PNGAF | RIVN · FY2025 |
|---|---|---|
| Revenue | — | $5.4B |
| Net income | — | (3.6B) |
| Revenue growth (yearly, multi-year) | — | 214.6% |
| Free cash flow | — | (2.5B) |
| Free cash flow margin | — | -46.2% |
| Net cash / (debt) | — | (3.1B) |
| ROIC | — | — |
| Return on equity | — | -65.6% |
| Gross margin | — | 2.7% |
| Operating margin | — | -66.5% |
| Net debt / EBITDA | — | -0.31x |
Figures are as reported by each company; latest fiscal year shown.
Where Rivian's cash went (FY2025)
- Capital spending
- $1.7B
- Buybacks
- $0
- Dividends
- $0
- Acquisitions
- $0
- Net debt issued / (repaid)
- $0
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free